Recurrent uterine corpus carcinoma Trials in St. Louis, United States
Conditions / Recurrent uterine corpus carcinoma / St. Louis, United States
Recurrent uterine corpus carcinoma has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01098630 | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | COMPLETED | — |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | COMPLETED | PHASE3 |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | UNKNOWN | PHASE2/PHASE3 |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | COMPLETED | PHASE2 |